Targeting metabolic inflammation in Parkinson's disease: Implications for prospective therapeutic strategies

Clinical and Experimental Pharmacology and Physiology

Volumn 39, Issue 6, 2012, Pages 577-585

  Lu, Ming ^a   Hu, Gang ^a  

^a NANJING MEDICAL UNIVERSITY   (China)

Author keywords

Insulin like growth factor 1; Interleukin 1 ; Metabolic inflammation; Nuclear factor B; Parkinson's disease; Tumour necrosis factor

Indexed keywords

ANTIINFLAMMATORY AGENT; IBUPROFEN; INSULIN; MINOCYCLINE; NEUROTOXIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; REACTIVE OXYGEN METABOLITE; SOMATOMEDIN C;

AGING; ANTIINFLAMMATORY ACTIVITY; BLOOD BRAIN BARRIER; DEGENERATIVE DISEASE; DIABETES MELLITUS; DISEASE ASSOCIATION; DISEASE COURSE; DISORDERS OF CARBOHYDRATE METABOLISM; DISORDERS OF LIPID METABOLISM; DOPAMINERGIC NERVE CELL; ENERGY METABOLISM; GLUCOSE METABOLISM; HUMAN; IMMUNITY; INFLAMMATION; LIPID METABOLISM; METABOLIC INFLAMMATION; NERVOUS SYSTEM INJURY; NIGRONEOSTRIATAL SYSTEM; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PANCREAS ISLET BETA CELL; PARKINSON DISEASE; PATHOPHYSIOLOGY; REVIEW; SUBSTANTIA NIGRA;

ANIMALS; ANTIPARKINSON AGENTS; BLOOD-BRAIN BARRIER; DRUG DELIVERY SYSTEMS; HUMANS; INFLAMMATION; PARKINSON DISEASE; PROSPECTIVE STUDIES; SIGNAL TRANSDUCTION;

EID: 84861670989     PISSN: 03051870     EISSN: 14401681     Source Type: Journal    
DOI: 10.1111/j.1440-1681.2011.05650.x     Document Type: Review

References (106)

1. Savitt JM, Dawson VL, Dawson TM. Diagnosis and treatment of Parkinson disease: Molecules to medicine. J. Clin. Invest. 2006; 116: 1744-54.
2. Di Giovanni G. Dopamine interaction with other neurotransmitter systems. Relevance in the pathophysiology and treatment of CNS disorders. CNS Neurosci. Ther. 2010; 16: 125-6.
3. Dauer W, Przedborski S. Parkinson's disease. Mechanisms and models. Neuron 2003; 39: 889-909.
4. Braak H, Del Tredici K, Rub U, de Vos RA, Jansen Steur EN, Braak E. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol. Aging 2003; 24: 197-211.
5. Gh Popescu BF, Nichol H. Mapping brain metals to evaluate therapies for neurodegenerative disease. CNS Neurosci. Ther. 2011; 17: 256-68.
6. Sulzer D, Schmitz Y. Parkinson's disease: Return of an old prime suspect. Neuron 2007; 55: 8-10.
7. Kincses ZT, Vecsei L. Pharmacological therapy in Parkinson's disease: Focus on neuroprotection. CNS Neurosci. Ther. 2011; 17: 345-67.
8. Hindle JV. Ageing, neurodegeneration and Parkinson's disease. Age Ageing 2010; 39: 156-61.
9. Priyadarshi A, Khuder SA, Schaub EA, Priyadarshi SS. Environmental risk factors and Parkinson's disease: A metaanalysis. Environ. Res. 2001; 86: 122-7.
10. Johnson CC, Gorell JM, Rybicki BA, Sanders K, Peterson EL. Adult nutrient intake as a risk factor for Parkinson's disease. Int. J. Epidemiol. 1999; 28: 1102-9.
11. Galati S, Di Giovanni G. Neuroprotection in Parkinson's disease: A realistic goal?CNS Neurosci. Ther. 2010; 16: 327-9.
12. Hu G, Jousilahti P, Nissinen A, Antikainen R, Kivipelto M, Tuomilehto J. Body mass index and the risk of Parkinson disease. Neurology 2006; 67: 1955-9.
13. Hu G, Jousilahti P, Bidel S, Antikainen R, Tuomilehto J. Type 2 diabetes and the risk of Parkinson's disease. Diabetes Care 2007; 30: 842-7.
14. Schernhammer E, Hansen J, Rugbjerg K, Wermuth L, Ritz B. Diabetes and the risk of developing Parkinson's disease in Denmark. Diabetes Care 2011; 34: 1102-8.
15. Xu Q, Park Y, Huang X et al. Diabetes and risk of Parkinson's disease. Diabetes Care 2011; 34: 910-15.
16. Andrabi SA, Dawson TM, Dawson VL. Mitochondrial and nuclear cross talk in cell death: Parthanatos. Ann. NY Acad. Sci. 2008; 1147: 233-41.
17. Maes M, Kubera M, Obuchowiczwa E, Goehler L, Brzeszcz J. Depression's multiple comorbidities explained by (neuro)inflammatory and oxidative & nitrosative stress pathways. Neuro. Endocrinol. Lett. 2011; 32: 7-24.
18. Milder DG. Progression of disease and a remedy. Causative role of macrophages and microglia: Remedial effect of immunomodulatory and immunosuppressive therapies 'in combination'. Med. Hypotheses 2006; 67: 736-9.
19. Cai D. NFkappaB-mediated metabolic inflammation in peripheral tissues versus central nervous system. Cell Cycle 2009; 8: 2542-8.
20. Sandyk R. The relationship between diabetes mellitus and Parkinson's disease. Int. J. Neurosci. 1993; 69: 125-30.
21. Moran LB, Graeber MB. Towards a pathway definition of Parkinson's disease: A complex disorder with links to cancer, diabetes and inflammation. Neurogenetics 2008; 9: 1-13.
22. D'Amelio M, Ragonese P, Callari G et al. Diabetes preceding Parkinson's disease onset. A case-control study. Parkinsonism Relat. Disord. 2009; 15: 660-4.
23. Driver JA, Smith A, Buring JE, Gaziano JM, Kurth T, Logroscino G. Prospective cohort study of type 2 diabetes and the risk of Parkinson's disease. Diabetes Care 2008; 31: 2003-5.
24. Morris JK, Bomhoff GL, Stanford JA, Geiger PC. Neurodegeneration in an animal model of Parkinson's disease is exacerbated by a high-fat diet. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2010; 299: R1082-90.
25. Morris JK, Bomhoff GL, Gorres BK et al. Insulin resistance impairs nigrostriatal dopamine function. Exp. Neurol. 2011; 231: 171-80.
26. de Leeuw van Weenen JE, Hu L, Jansen-Van Zelm K et al. Four weeks high fat feeding induces insulin resistance without affecting dopamine release or gene expression patterns in the hypothalamus of C57Bl6 mice. Brain Res. 2009; 1250: 141-8.
27. Arvanitakis Z, Wilson RS, Schneider JA, Bienias JL, Evans DA, Bennett DA. Diabetes mellitus and progression of rigidity and gait disturbance in older persons. Neurology 2004; 63: 996-1001.
28. Arvanitakis Z, Wilson RS, Bienias JL, Bennett DA. Diabetes and parkinsonian signs in older persons. Alzheimer Dis. Assoc. Disord. 2007; 21: 144-9.
29. Moroo I, Yamada T, Makino H et al. Loss of insulin receptor immunoreactivity from the substantia nigra pars compacta neurons in Parkinson's disease. Acta Neuropathol. 1994; 87: 343-8.
30. Kroner Z. The relationship between Alzheimer's disease and diabetes: Type 3 diabetes?Altern. Med. Rev. 2009; 14: 373-9.
31. Laron Z. Insulin and the brain. Arch. Physiol. Biochem. 2009; 115: 112-16.
32. Yu Y, Kastin AJ, Pan W. Reciprocal interactions of insulin and insulin-like growth factor I in receptor-mediated transport across the blood-brain barrier. Endocrinology 2006; 147: 2611-15.
33. Wallum BJ, Taborsky GJ Jr, Porte D Jr et al. Cerebrospinal fluid insulin levels increase during intravenous insulin infusions in man. J. Clin. Endocrinol. Metab. 1987; 64: 190-4.
34. Takahashi M, Yamada T, Tooyama I et al. Insulin receptor mRNA in the substantia nigra in Parkinson's disease. Neurosci. Lett. 1996; 204: 201-4.
35. Murzi E, Contreras Q, Teneud L et al. Diabetes decreases limbic extracellular dopamine in rats. Neurosci. Lett. 1996; 202: 141-4.
36. Figlewicz DP, Brot MD, McCall AL, Szot P. Diabetes causes differential changes in CNS noradrenergic and dopaminergic neurons in the rat: A molecular study. Brain Res. 1996; 736: 54-60.
37. Morris JK, Zhang H, Gupte AA, Bomhoff GL, Stanford JA, Geiger PC. Measures of striatal insulin resistance in a 6-hydroxydopamine model of Parkinson's disease. Brain Res. 2008; 1240: 185-95.
38. Figlewicz DP, Szot P, Chavez M, Woods SC, Veith RC. Intraventricular insulin increases dopamine transporter mRNA in rat VTA/substantia nigra. Brain Res. 1994; 644: 331-4.
39. Liu Z, Wang Y, Zhao W et al. Peptide derived from insulin with regulatory activity of dopamine transporter. Neuropharmacology 2001; 41: 464-71.
40. Lozovsky D, Saller CF, Kopin IJ. Dopamine receptor binding is increased in diabetic rats. Science 1981; 214: 1031-3.
41. Jimenez-Jimenez FJ, Molina JA, Vargas C et al. Normal cerebrospinal fluid levels of insulin in patients with Parkinson's disease. J. Neural Transm. 2000; 107: 445-9.
42. Mashayekhi F, Mirzajani E, Naji M, Azari M. Expression of insulin-like growth factor-1 and insulin-like growth factor binding proteins in the serum and cerebrospinal fluid of patients with Parkinson's disease. J. Clin. Neurosci. 2010; 17: 623-7.
43. Godau J, Herfurth M, Kattner B, Gasser T, Berg D. Increased serum insulin-like growth factor 1 in early idiopathic Parkinson's disease. J. Neurol. Neurosurg. Psychiatry 2010; 81: 536-8.
44. de Lau LM, Koudstaal PJ, Hofman A, Breteler MM. Serum cholesterol levels and the risk of Parkinson's disease. Am. J. Epidemiol. 2006; 164: 998-1002.
45. Miyake Y, Tanaka K, Fukushima W et al. Case-control study of risk of Parkinson's disease in relation to hypertension, hypercholesterolemia, and diabetes in Japan. J. Neurol. Sci. 2010; 293: 82-6.
46. Huang X, Chen H, Miller WC et al. Lower low-density lipoprotein cholesterol levels are associated with Parkinson's disease. Mov. Disord. 2007; 22: 377-81.
47. Ikeda K, Nakamura Y, Kiyozuka T et al. Serological profiles of urate, paraoxonase-1, ferritin and lipid in Parkinson's disease: Changes linked to disease progression. Neurodegener. Dis. 2011; 8: 252-8.
48. Simon KC, Chen H, Schwarzschild M, Ascherio A. Hypertension, hypercholesterolemia, diabetes, and risk of Parkinson disease. Neurology 2007; 69: 1688-95.
49. Alimov I, Nazhmidinova MN, Ganiev KhG. Changes in lipid metabolism in patients with Parkinson disease after combined treatment with l-deprenil (iumex) and antiparkinson drugs. Zh. Nevropatol. Psikhiatr. Im S.S. Korsakova 1990; 90: 35-8 (in Russian).
50. Selley ML. Simvastatin prevents 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine-induced striatal dopamine depletion and protein tyrosine nitration in mice. Brain Res. 2005; 1037: 1-6.
51. Stepien K, Tomaszewski M, Czuczwar SJ. Neuroprotective properties of statins. Pharmacol. Rep. 2005; 57: 561-9.
52. Jick H, Zornberg GL, Jick SS, Seshadri S, Drachman DA. Statins and the risk of dementia. Lancet 2000; 356: 1627-31.
53. Lieberman A, Lyons K, Levine J, Myerburg R. Statins, cholesterol, Co-enzyme Q10, and Parkinson's disease. Parkinsonism Relat. Disord. 2005; 11: 81-4.
54. Becker C, Jick SS, Meier CR. Use of statins and the risk of Parkinson's disease: A retrospective case-control study in the UK. Drug Saf. 2008; 31: 399-407.
55. Popescu BO, Toescu EC, Popescu LM et al. Blood-brain barrier alterations in ageing and dementia. J. Neurol. Sci. 2009; 283: 99-106.
56. Kortekaas R, Leenders KL, van Oostrom JC et al. Blood-brain barrier dysfunction in parkinsonian midbrain in vivo. Ann. Neurol. 2005; 57: 176-9.
57. Chen X, Lan X, Roche I, Liu R, Geiger JD. Caffeine protects against MPTP-induced blood-brain barrier dysfunction in mouse striatum. J. Neurochem. 2008; 107: 1147-57.
58. Yan E, Castillo-Melendez M, Nicholls T, Hirst J, Walker D. Cerebrovascular responses in the fetal sheep brain to low-dose endotoxin. Pediatr. Res. 2004; 55: 855-63.
59. Yasuda T, Fukuda-Tani M, Nihira T et al. Correlation between levels of pigment epithelium-derived factor and vascular endothelial growth factor in the striatum of patients with Parkinson's disease. Exp. Neurol. 2007; 206: 308-17.
60. Zlokovic BV. The blood-brain barrier in health and chronic neurodegenerative disorders. Neuron 2008; 57: 178-201.
61. Rite I, Machado A, Cano J, Venero JL. Blood-brain barrier disruption induces in vivo degeneration of nigral dopaminergic neurons. J. Neurochem. 2007; 101: 1567-82.
62. Machado A, Herrera AJ, Venero JL et al. Peripheral inflammation increases the damage in animal models of nigrostriatal dopaminergic neurodegeneration: Possible implication in Parkinson's disease incidence. Parkinsons Dis. 2011; 2011: 393769.
63. Kreutzberg GW. Microglia: A sensor for pathological events in the CNS. Trends Neurosci. 1996; 19: 312-18.
64. Ho G, Kumar S, Ke Z et al. Imidazolium salt (DBZIM) reduces gliosis in mice treated with neurotoxicant 2′-CH(3)-MPTP. CNS Neurosci. Ther. 2011; 17: 148-57.
65. Perry VH, Nicoll JA, Holmes C. Microglia in neurodegenerative disease. Nat Rev. Neurol. 2010; 6: 193-201.
66. Whitton PS. Inflammation as a causative factor in the aetiology of Parkinson's disease. Br. J. Pharmacol. 2007; 150: 963-76.
67. Ransohoff RM, Perry VH. Microglial physiology: Unique stimuli, specialized responses. Annu. Rev. Immunol. 2009; 27: 119-45.
68. Kim SU, de Vellis J. Microglia in health and disease. J. Neurosci. Res. 2005; 81: 302-13.
69. Banisadr G, Rostene W, Kitabgi P, Parsadaniantz SM. Chemokines and brain functions. Curr. Drug Targets Inflamm. Allergy 2005; 4: 387-99.
70. Cartier L, Hartley O, Dubois-Dauphin M, Krause KH. Chemokine receptors in the central nervous system. Role in brain inflammation and neurodegenerative diseases. Brain Res. Brain Res. Rev. 2005; 48: 16-42.
71. Biber K, De Jong EK, van Weering HR, Boddeke HW. Chemokines and their receptors in central nervous system disease. Curr. Drug Targets 2006; 7: 29-46.
72. Pott Godoy MC, Tarelli R, Ferrari CC, Sarchi MI, Pitossi FJ. Central and systemic IL-1 exacerbates neurodegeneration and motor symptoms in a model of Parkinson's disease. Brain 2008; 131: 1880-94.
73. Pott Godoy MC, Ferrari CC, Pitossi FJ. Nigral neurodegeneration triggered by striatal AdIL-1 administration can be exacerbated by systemic IL-1 expression. J. Neuroimmunol. 2010; 222: 29-39.
74. He Y, Le WD, Appel SH. Role of Fcgamma receptors in nigral cell injury induced by Parkinson disease immunoglobulin injection into mouse substantia nigra. Exp. Neurol. 2002; 176: 322-7.
75. Brochard V, Combadiere B, Prigent A et al. Infiltration of CD4+ lymphocytes into the brain contributes to neurodegeneration in a mouse model of Parkinson disease. J. Clin. Invest. 2009; 119: 182-92.
76. Reynolds AD, Banerjee R, Liu J, Gendelman HE, Mosley RL. Neuroprotective activities of CD4+ CD25+ regulatory T cells in an animal model of Parkinson's disease. J. Leukoc. Biol. 2007; 82: 1083-94.
77. Reynolds AD, Stone DK, Mosley RL, Gendelman HE. Proteomic studies of nitrated alpha-synuclein microglia regulation by CD4+ CD25+ T cells. J. Proteome Res. 2009; 8: 3497-511.
78. Carta AR, Pisanu A, Carboni E. Do PPAR-gamma agonists have a future in Parkinson's disease therapy?Parkinsons Dis. 2011; 2011: 689181.
79. Dobbs RJ, Charlett A, Purkiss AG, Dobbs SM, Weller C, Peterson DW. Association of circulating TNF-alpha and IL-6 with ageing and parkinsonism. Acta Neurol. Scand. 1999; 100: 34-41.
80. Reale M, Iarlori C, Thomas A et al. Peripheral cytokines profile in Parkinson's disease. Brain Behav. Immun. 2009; 23: 55-63.
81. Hisanaga K, Asagi M, Itoyama Y, Iwasaki Y. Increase in peripheral CD4 bright+ CD8 dull+ T cells in Parkinson disease. Arch. Neurol. 2001; 58: 1580-3.
82. Bas J, Calopa M, Mestre M et al. Lymphocyte populations in Parkinson's disease and in rat models of parkinsonism. J. Neuroimmunol. 2001; 113: 146-52.
83. Przuntek H, Muller T, Riederer P. Diagnostic staging of Parkinson's disease: Conceptual aspects. J. Neural Transm. 2004; 111: 201-16.
84. Weller C, Oxlade N, Dobbs SM, Dobbs RJ, Charlett A, Bjarnason IT. Role of inflammation in gastrointestinal tract in aetiology and pathogenesis of idiopathic parkinsonism. FEMS Immunol. Med. Microbiol. 2005; 44: 129-35.
85. McGeer PL, Itagaki S, Boyes BE, McGeer EG. Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson's and Alzheimer's disease brains. Neurology 1988; 38: 1285-91.
86. Yamada T, McGeer PL, McGeer EG. Lewy bodies in Parkinson's disease are recognized by antibodies to complement proteins. Acta Neuropathol. 1992; 84: 100-4.
87. Hirsch EC, Hunot S. Neuroinflammation in Parkinson's disease: A target for neuroprotection?Lancet Neurol. 2009; 8: 382-97.
88. Cao JJ, Li KS, Shen YQ. Activated immune cells in Parkinson's disease. J. Neuroimmune Pharmacol. 2011; 6: 323-9.
89. Orr CF, Rowe DB, Mizuno Y, Mori H, Halliday GM. A possible role for humoral immunity in the pathogenesis of Parkinson's disease. Brain 2005; 128: 2665-74.
90. Hadjiconstantinou M, Neff NH. Enhancing aromatic l-amino acid decarboxylase activity: Implications for l-DOPA treatment in Parkinson's disease. CNS Neurosci. Ther. 2008; 14: 340-51.
91. Blandini F. Neuroprotection by rasagiline: A new therapeutic approach to Parkinson's disease?CNS Drug Rev. 2005; 11: 183-94.
92. Chen H, Zhang SM, Hernan MA et al. Nonsteroidal anti-inflammatory drugs and the risk of Parkinson disease. Arch. Neurol. 2003; 60: 1059-64.
93. Chen H, Jacobs E, Schwarzschild MA et al. Nonsteroidal antiinflammatory drug use and the risk for Parkinson's disease. Ann. Neurol. 2005; 58: 963-7.
94. Kim HS, Suh YH. Minocycline and neurodegenerative diseases. Behav. Brain Res. 2009; 196: 168-79.
95. Tomas-Camardiel M, Rite I, Herrera AJ et al. Minocycline reduces the lipopolysaccharide-induced inflammatory reaction, peroxynitrite-mediated nitration of proteins, disruption of the blood-brain barrier, and damage in the nigral dopaminergic system. Neurobiol. Dis. 2004; 16: 190-201.
96. Martin H. Role of PPAR-gamma in inflammation. Prospects for therapeutic intervention by food components. Mutat. Res. 2010; 690: 57-63.
97. Carta AR, Frau L, Pisanu A, Wardas J, Spiga S, Carboni E. Rosiglitazone decreases peroxisome proliferator receptor-gamma levels in microglia and inhibits TNF-alpha production: New evidences on neuroprotection in a progressive Parkinson's disease model. Neuroscience 2011; 194: 250-61.
98. Schintu N, Frau L, Ibba M et al. PPAR-gamma-mediated neuroprotection in a chronic mouse model of Parkinson's disease. Eur. J. Neurosci. 2009; 29: 954-63.
99. Jiang Q, Yan Z, Feng J. Neurotrophic factors stabilize microtubules and protect against rotenone toxicity on dopaminergic neurons. J. Biol. Chem. 2006; 281: 29391-400.
100. Dunn JD, Castro AJ. Altered but persisting circadian fluctuations in plasma corticosterone levels following medial forebrain bundle ablation. Neurosci. Lett. 1980; 19: 93-6.
101. Sutherland GT, Matigian NA, Chalk AM et al. A cross-study transcriptional analysis of Parkinson's disease. PLoS ONE 2009; 4: e4955.
102. Zawada WM, Kirschman DL, Cohen JJ, Heidenreich KA, Freed CR. Growth factors rescue embryonic dopamine neurons from programmed cell death. Exp. Neurol. 1996; 140: 60-7.
103. Cheng B, Maffi SK, Martinez AA, Acosta YP, Morales LD, Roberts JL. Insulin-like growth factor-I mediates neuroprotection in proteasome inhibition-induced cytotoxicity in SH-SY5Y cells. Mol. Cell. Neurosci. 2011; 47: 181-90.
104. Wang L, Yang HJ, Xia YY, Feng ZW. Insulin-like growth factor 1 protects human neuroblastoma cells SH-EP1 against MPP+-induced apoptosis by AKT/GSK-3beta/JNK signaling. Apoptosis 2010; 15: 1470-9.
105. Avila-Gomez IC, Velez-Pardo C, Jimenez-Del-Rio M. Effects of insulin-like growth factor-1 on rotenone-induced apoptosis in human lymphocyte cells. Basic Clin. Pharmacol. Toxicol. 2010; 106: 53-61.
106. Sun X, Huang L, Zhang M, Sun S, Wu Y. Insulin like growth factor-1 prevents 1-mentyl-4-phenylphyridinium-induced apoptosis in PC12 cells through activation of glycogen synthase kinase-3beta. Toxicology 2010; 271: 5-12.